Workflow
又新受理19家IPO!今年至今获受理共80家
梧桐树下V·2025-06-25 11:15

Group 1 - A total of 19 IPOs were accepted by Shenzhen and Beijing Stock Exchanges from June 23 to June 24, including 1 from Shenzhen Main Board, 4 from Shenzhen ChiNext, and 14 from Beijing Stock Exchange [1] - As of June 24, 2025, a total of 80 IPO projects have been accepted across the three major exchanges, with 14 from Shanghai, 17 from Shenzhen, and 49 from Beijing [2] Group 2 - Hangzhou Fu'en Co., Ltd. was accepted for IPO on Shenzhen Main Board on June 24, with a registered capital of 175 million yuan [3] - The company focuses on sustainable development and is a global supplier of eco-friendly fabrics, primarily producing recycled fabrics [4] - The controlling shareholder is Paiya Holdings, holding 36.57% of shares, with actual controllers being Wang Neili, Wang Xuelin, and Wang Enwei, collectively controlling 83.89% of voting rights [5] - The company reported revenues of 1.76 billion yuan in 2022, 1.52 billion yuan in 2023, and projected 1.81 billion yuan in 2024, with net profits of 276 million yuan, 227 million yuan, and 254 million yuan respectively [6][7] - The company meets the listing criteria of Shenzhen Stock Exchange, with positive net profits over the last three years and a cumulative net profit of no less than 200 million yuan [8] Group 3 - Suzhou Betterly Polymer Materials Co., Ltd. was accepted for IPO on ChiNext on June 24, with a registered capital of 197 million yuan [13] - The company specializes in the R&D, production, and sales of electronic materials and new chemical materials, with applications in photovoltaic, 3C electronics, and new energy vehicles [14] - The controlling shareholder is Wang Quan, holding 37.26% of shares, with actual control by Wang Quan and Ouyang Xufeng [15] - The company reported revenues of 635 million yuan in 2022, 2.27 billion yuan in 2023, and projected 2.52 billion yuan in 2024, with net profits of 13 million yuan, 84 million yuan, and 95 million yuan respectively [16][17] - The company meets the listing criteria of ChiNext, with positive net profits over the last two years and a cumulative net profit of no less than 100 million yuan [19] Group 4 - Nantong Lianya Pharmaceutical Co., Ltd. was accepted for IPO on ChiNext on June 24, with a registered capital of 757.86 million yuan [24] - The company is a R&D-driven high-tech enterprise focusing on complex drug formulations, primarily producing high-end generic drugs [26] - The controlling shareholder is Lianya Cayman, holding 22.62% of shares, with actual controllers being Zhang Guohua and others [27] - The company reported revenues of 550 million yuan in 2022, 700 million yuan in 2023, and projected 866 million yuan in 2024, with net profits of 68 million yuan, 87 million yuan, and 181 million yuan respectively [28][29] - The company meets the listing criteria with positive net profits over the last two years and a cumulative net profit of no less than 100 million yuan [30] Group 5 - Guizhou Southern Dairy Co., Ltd. was accepted for IPO on Beijing Stock Exchange on June 24, with a registered capital of 150 million yuan [35] - The company is engaged in the manufacturing and sales of dairy products and related beverages, including various low-temperature and room-temperature dairy products [36] - The controlling shareholder is Guiyang Agricultural Investment Group, holding 51.01% of shares, with significant influence from the Guiyang State-owned Assets Supervision and Administration Commission [37] - The company reported revenues of 1.58 billion yuan in 2022, 1.80 billion yuan in 2023, and projected 1.82 billion yuan in 2024, with net profits of 165 million yuan, 199 million yuan, and 207 million yuan respectively [38][39] - The company meets the listing criteria with a market value of no less than 200 million yuan and positive net profits over the last two years [40] Group 6 - Zhongjiankangqiao Pharmaceutical Group Co., Ltd. was accepted for IPO on Beijing Stock Exchange on June 24, with a registered capital of 75.40 million yuan [45] - The company focuses on chronic disease medications, particularly for cardiovascular diseases, and has established a comprehensive industry chain [46] - The controlling shareholder is Furong Kangda, holding 57.58% of shares, with actual controllers being Liu Zongjie and others [47] - The company reported revenues of 267 million yuan in 2022, 343 million yuan in 2023, and projected 446 million yuan in 2024, with net profits of 61 million yuan, 111 million yuan, and 103 million yuan respectively [48][49] - The company meets the listing criteria with a market value of no less than 200 million yuan and positive net profits over the last two years [51] Group 7 - Beijing Kangmite Technology Co., Ltd. was accepted for IPO on Beijing Stock Exchange on June 24, with a registered capital of 120.20 million yuan [56] - The company specializes in the R&D, production, and sales of electronic packaging materials and high-performance modified plastics [57]